Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer ...Middle East

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with...

Hence then, the article about akeso announces first patient dosed in phase i trial of personalized mrna vaccine ak154 as monotherapy or in combination with cadonilimab or ivonescimab for adjuvant treatment of pancreatic cancer was published today ( Monday 10/11/2025 - 02:41 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer )

Also on site :

• Hilton assisted living facility evacuated overnight due to water leak
• Here’s how 2025 killed old-school diplomacy
• Quantum Computing in Financial Services Market Set to Reach USD 6.3 Billion by 2032 as Banks Move from Experimentation to Quantum Advantage .. DataM Intelligence